sotatercept news

Strong oncology and animal health sales, positive trial results, and strategic acquisitions drive growth. 2026 outlook projects sales up to $67B, with EPS impacted by acquisition charges.

EU CHMP backs expanded WINREVAIR™ use for PAH, covering WHO FC II-IV. Decision by European Commission expected Q1 2026.

WINREVAIR reduced pulmonary vascular resistance in Phase 2 CADENCE study, supporting Phase 3 development for treating pulmonary hypertension due to heart failure with preserved ejection fraction.

Sales rose 4% to $17.3B. KEYTRUDA up 10%, GARDASIL down 24%. GAAP EPS $2.32, Non-GAAP $2.58. FDA approved KEYTRUDA QLEX. Acquired Verona Pharma. Full-year sales outlook: $64.5B-$65B.

WINREVAIR, now approved for PAH, improves exercise capacity, reduces clinical worsening risks, and shows significant efficacy in the ZENITH trial. Monitor hemoglobin and platelets during treatment.

WINREVAIR, when started within a year of PAH diagnosis, significantly lowers clinical worsening risk. Safety profile aligns with previous trials. Results shared at ERS 2025 and published in NEJM.